Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 入组人数
- 44
- 试验地点
- 1
- 主要终点
- Total kidney volume (TKV)
研究概览
简要总结
The EMPA-PKD trial is assessing the safety of empagliflozin in patients with rapid progressive ADPKD with and without concomitant tolvaptan use by monitoring kidney growth and the rate of loss of kidney function.
详细描述
In autosomal dominant polycystic kidney disease (ADPKD) formation of cysts in the kidneys causes destruction of functional parenchyma and loss of kidney function, which may progress to end-stage kidney disease. Tolvaptan is the only drug specifically approved for slowing down the progression of ADPKD. Sodium glucose cotransporter 2 inhibitors (SGLT2i) might provide additional benefits but there is currently no information on safety and outcome effects of SGLT2i in patients with ADPKD, as these patients were excluded in the landmark SGLT2i trials. In an investigator-initiated, double-blind, mono-center, placebo-controlled, randomized clinical trial the EMPA-PKD study is assessing the safety of empagliflozin in patients with rapid progressive ADPKD with and without concomitant tolvaptan use by monitoring kidney growth and the rate of loss of kidney function.
44 participants will be randomly allocated (1:1) to receive a daily dose of either empagliflozin (10 mg/day) or placebo for 18 months. Patients will be stratified according to concomitant tolvaptan use. The primary endpoint is progression of cystic kidney growth by monitoring MRI-based changes in total kidney volume and the secondary endpoint is exploring changes in glomerular filtration rate. Additional endpoints include adverse events and changes in copeptin levels, albuminuria and blood pressure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female* patients ≥ 18 of age
- •Screening eGFR ≥ 25 and ≤ 90 mL/min/1.73 m2 if age ≥ 18 and ≤50 years or Screening eGFR ≥ 25 and ≤ 65 mL/min/1.73 m2 if age > 50 years
- •ADPKD diagnosed by unified criteria (combination of family history, ultrasound, MRI/CT, genotyping as needed)
- •Mayo Class I C, D, E
- •Patients with and without tolvaptan use will be included. Patients with tolvaptan use will be included if tolvaptan has been taken for ≥ 3 months at study entry.
- •Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures
- •Evidence of signed written informed consent.
- •Exclusion criteria:
- •Kidney or any other solid organ transplant recipient
- •Currently receiving SGLT2-inhibitor
- •Concomitant treatment with steroids or any other immunosuppressive agent
- •Hypersensitivity to the active principle (Empagliflozin) or any of the excipients (e.g. lactose)
- •Ketoacidosis (laboratory based) in the past 5 years
- •Type 1 diabetes mellitus
- •Ongoing urinary tract- or genital infections
- •Inability to fully understand the possible risks and benefits related to study participation
- •Inability to undergo MRI exam (e.g. implanted medical devices)
- •Women who are pregnant or breastfeeding
- •Unwilling to practice acceptable methods of birth control during study participation
- •Participation in another clinical trial (other investigational drugs or devices at the time of enrolment or within 30 days prior to enrolment)
排除标准
- 未提供
研究组 & 干预措施
Empagliflozin 10 milligram (MG)
干预措施: Empagliflozin 10 MG (Drug)
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Total kidney volume (TKV)
时间窗: 18 months
Relative change from baseline TKV (percent/year) to month 18 of treatment.
次要结局
- Estimated glomerular filtration rate (eGFR)(18 months)